REGULATION A+ OFFERING ENGAGEMENT AGREEMENTRegulation A+ Offering Engagement Agreement • November 17th, 2020 • American Hospitality Properties REIT, Inc. • Real estate • Wisconsin
The purpose of this engagement agreement (the “Agreement”) is to outline our agreement in principle pursuant to which KCD Financial, Inc. ( “KCD” or “Dealer Manager”) will act as the lead managing Dealer Manager in connection with a best efforts qualified Regulation A+ Tier 2 offering by American Hospitality Properties REIT, Inc., a Delaware corporation (the “Company”), of up to $50,000,000 of shares of common stock (the “Shares”) to the public at $10.00 per share as more fully described in the Company’s offering circular dated July 23, 2019 (the “Offering Circular” or “OC”) filed with the Securities and Exchange Commission pursuant to Rule 253(g)(2).
AMENDED & RESTATED REGULATION A+ OFFERING ENGAGEMENT AGREEMENTRegulation A+ Offering Engagement Agreement • February 1st, 2018 • Neurmedix, Inc. • Pharmaceutical preparations • California
The purpose of this engagement agreement (the “Agreement”) is to outline our agreement in principle pursuant to which WestPark Capital, Inc. ( “WestPark” or “Selling Agent”) will act as the lead managing selling agent and book runner in connection with a best efforts qualified primary offering by Neurmedix, Inc., a Delaware Corporation (the “Company”) of up to $50,000,000 of common stock, no par value per share, of the Company, and such other securities of the Company as may be appropriate on terms and conditions to be mutually agreed between the Company and the Selling Agent, as described herein.
REGULATION A+ OFFERING ENGAGEMENT AGREEMENTRegulation A+ Offering Engagement Agreement • April 30th, 2019 • Neurmedix, Inc. • Pharmaceutical preparations • California
The purpose of this Regulation A+ Engagement Agreement (the “Agreement”) is to outline our agreement in principle pursuant to which NMS Capital Advisors, LLC (“NMS” or “Selling Agent”) will act as the lead managing selling agent in connection with a best efforts qualified Regulation A+ (Tier 2) offering by NeurMedix, Inc., a Delaware Corporation (the “Company”) of up to $50,000,000 of common stock, no par value per share, of the Company, and such other securities of the Company as may be appropriate on terms and conditions to be mutually agreed between the Company and the Selling Agent, as described herein. Each of NMS and the Company may be referred to herein as a “Party” and collectively, as the “Parties.”
